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AbstrAct
Background Pembrolizumab is a new drug approved in 
several countries for second-line therapy in non-small cell 
lung cancer (NSCLC) being programmed cell death ligand 
(PD-L1) positive. This drug has a high cost, and the cost-
effectiveness ratio has been debated.
Patients and methods The budget impact to the Northern 
Norwegian Regional Health Authority trust of implementing 
pembrolizumab in second-line therapy in patients with 
PD-L1-positive NSCLC was calculated. A model was 
developed employing data from the Cancer Registry of 
Norway, the KEYNOTE-010 study, the price list from The 
Hospital Pharmacy of North Norway, the cost of analysing 
PD-L1 expression and the cost of travelling. Today’s 
cost of second-line therapy was compared with the new 
standard employing pembrolizumab. The sale price of 
pembrolizumab in Norway was not published due to price 
confidentiality. Norwegian krone (NKr) was converted into 
Euros (€) at a rate of 1€=Nkr 8.8138. (Bank of Norway, 
21 February 2017).
Results 105 new patients were identified available 
for pembrolizumab per year. The annual cost of 
pembrolizumab was €5.2 million, hospital pharmacy 
administration costs €0.1 million, PD-L1 testing 
€0.3 million, oncologist/pulmonologist/nurses 
€0.2 million, radiology €0.06 million and transportation 
€0.4 million. Savings due to avoided present second-line 
therapy was calculated €0.4 million. Consequently, the 
cost of implementing pembrolizumab was €5.5 million and 
the annual budget impact was €5.0 million. A mean gain 
of at least 9 months per patient treated was necessary to 
make pembrolizumab cost-effective.
Conclusions The net budget impact of pembrolizumab 
was €5.0 million. The expenditure could not be indicated 
cost-effective. Price confidentiality is a growing problem 
in health economics and it has become a ‘menu without 
prices’ setting.
IntroductIon
In Norway, about 3000 patients are diagnosed 
with lung cancer each year and the figure is 
expected to rise to 3700 cases in 2025.1–4 Most 
cases are non-small cell lung cancer (NSCLC), 
and the median age at diagnosis is 70 years. 
A total of 85% of all patients are initially 
diagnosed with or develop advanced stage of 
disease (stage III or IV) during follow-up.
First-line treatment of metastatic NSCLC 
has traditionally been the use of a platinum 
doublet therapy. The combination of carbo-
platin and vinorelbin has shown less toxicity.5 
Patients with epidermal growth factor 
receptor (EGFR) mutations or anaplastic 
lymphoma kinase (ALK) mutations have also 
been offered specific targeting treatments.1 
Tyrosine kinase (TK) inhibitors (erlotinib, 
gefitinib and afatinib) have been employed 
in EGFR mutations and crizotinib in ALK 
translocations. Patients progressing on first-
line therapy experiencing good performance 
status (Eastern Cooperative Oncology Group 
(ECOG) status 0–1) have traditionally been 
offered single-drug regimens consisting of 
docetaxel, pemetrexed, erlotinib or gemcit-
abine. The median overall survival has been 
reported between 5.7–9.3 months1 and 1-year 
overall survival around 30%.5 6
Pembrolizumab (Keytruda) is a new 
drug, recently approved for second-line 
treatment of patients with advanced or meta-
static NSCLC with programmed cell death 
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Key questions
What is already known about this subject?
 ► This is a new drug in NSCLC being PD-L1 positive. 
It is costly. The cost-effectiveness has been heavily 
debated.
What does this study add?
 ► This study documents the budget impact in northern 
Norway and illustrates the costs and savings that 
have to be considered. It also documents the 
necessary gain needed to make this drug cost-
effective.
How might this impact on clinical practice?
 ► The possible impact may be an awareness of the 
costs and the importance of price negotiations. 
Hopefully, price secrecy may be abandoned.
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Figure 1 The model employed.
ligand (PD-L1) expression.7–9 Due to the significant 
cost of pembrolizumab, this therapy will obviously have 
a significant impact on the hospitals’ budgets. In this 
study, we aimed to clarify this impact and discuss whether 
this therapy can be considered cost-effective.
Materials and methods
We calculated the budget impact to the Northern Norwe-
gian Regional Healthcare Authority (NNRHA) trust of 
implementing pembrolizumab (instead of docetaxel 
or pemetrexed) as standard second-line therapy in 
advanced (stage III) or metastatic (stage IV) NSCLC 
with PD-L1 expression. A model-based cost-minimising 
analysis was performed. The model included two alter-
natives: pembrolizumab 2 mg/kg or standard second-line 
therapy.1 Alternatives employed in second-line therapy 
in Norway are docetaxel, pemetrexed, navelbine, erlo-
tinib and gefitinib. The majority of patients are treated 
with docetaxel and some with pemetrexed (non-squa-
mous cell carcinoma). Two clinicians, working daily with 
patients with lung cancer at our two major hospitals, were 
included in the development of the model. The model is 
shown in figure 1.
Population
Norwegian guidelines1 state that immunotherapy with 
pembrolizumab should be considered in patients with 
good performance status (ECOG 0–1) and PD-L1-ex-
pressing NSCLC. The PD-L1 expression was set to at least 
1%.1 7 According to Norwegian data,3 northern Norway 
had 10.3% of all lung cancers in Norway. In 2015, there 
were 3035 cases, 84% of them were NSCLC and 70% of 
patients had an advanced stage of disease (stage III or IV) 
at the time of diagnosis.4 Half of the patients with localised 
disease developed distant metastasis during follow-up. 
Consequently, 85% of patients were potential candidates 
for pembrolizumab therapy. However, according to the 
clinicians’ experience, 30% of these patients would, due 
to poor performance status (ECOG >1) and/or short life 
expectancy (<3 months), not be candidates for second-
line chemotherapy. Furthermore, two-thirds do have a 
PD-L1 expression in at least 1% of tumour cells.7
costs
All costs and savings were calculated from the health-
care’s point of view, and Norwegian krone (NKr) was 
converted into Euros (€) at a rate of 1€=8.8138 NKr 
(Bank of Norway, 21 February 2017). Cost of the analysis 
of PD-L1 status was based on data from the Department 
of Pathology at the University Hospital of North Norway 
(UNN) and Nordland Hospital (NH), respectively. 
Together, they argued for one biomedical laboratory 
scientist (€79 421/year) and the total need for clin-
ical pathologist resources was calculated a half position 
(€110 959/year). Costs connected to personnel included 
employers’ costs due to pension and social costs (30%). 
The cost per Dako-kit was €7148; 380 tests per year and 
25 cases per kit was calculated. Consequently, the total 
number of kits was 25 annually.
MRI or CT is the most commonly employed imaging 
tool to document the disease status and evaluate treatment 
effects in NSCLC. On the basis of the clinicians’ advice, 
we calculated CT as the main tool, and 5% of patients 
in the pembrolizumab arm were assumed undergoing 
additionally MRI due to suspected cerebral metastasis. 
Furthermore, a total of 20% of patients were concluded 
undergoing CT-guided biopsy to achieve the necessary 
tissue to clarify PD-L1 status. The 2016 price list of the 
Norwegian Health Economics Administration (NHEA) 
was used.10 Norwegian hospital trusts are financed partly 
on activity and partly on basic funding, with equal shares. 
Consequently, the NHEA figures were doubled when 
calculating costs. Evaluation was performed every ninth 
week during treatment.
Drug cost and drug administration cost were obtained 
from the Hospital Pharmacy of North Norway, as of 
1 January 2017. The selling price of pembrolizumab is 
a secret between the manufacturer Merck, Sharp & Dohme 
(MSD) and the Norwegian Hospital Procurement trust. 
Consequently, due to price confidentiality, we cannot 
publish data making the price available to third parties. 
The mean treatment time in the docetaxel arm was 4.7 
cycles and consequently 5.7 outpatient visits were calcu-
lated.7 In the pembrolizumab arm, several patients were 
under therapy when the study was reported. On the basis 
of the data on the Norwegian Medicines Agency (NMA),9 
Huang and colleagues,11 results presented at 17th World 
Conference on Lung Cancer (WCLC) in Vienna in 
December 2016 and the qualified guess of our group 
of clinicians, we estimated the mean number of cycles. 
The number of cycles cannot be given due to price 
confidentiality. Furthermore, patients’ mean weight was 
calculated to 75 kg and the height was 179.6 cm, based on 
data from Statistics Norway (www. ssb. no). The Mosteller 
method12 was employed to calculate the body surface area 
(1.93 m2). We did not reveal any information about signif-
icant differences in treatments following progression in 
the docetaxel or pembrolizumab arm. We, therefore, did 
not include any differences in costs of third-line therapy 
or costs of end-of-life therapy.
The cost of present standard second-line therapy was 
calculated according to the selling price of docetaxel and 
pemetrexed at the Pharmacy of Northern Norway trust. 
A dose of 75 mg/m2 was employed and the pharmacy 
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production/administration cost was included. Similarly, 
the cost of pemetrexed was calculated at a dose of 500 mg/
m2. The selling price of pemetrexed and docetaxel was 
confidential between the manufacturers and the Norwe-
gian Hospital Procurement trust. To avoid revealing trade 
secrets and after a careful comparison of the calculated 
costs and the refunds according to the diagnosis-related 
group (DRG) system (DRG 856D, €1227), we concluded 
to employ the latter in our calculation.13 This refund was 
meant to compensate the expenses, but negotiations over 
price had somewhat lowered the cost.
The extra resources of oncologist/pulmonologist/
nurses needed, due to prolonged therapy, were estimated 
by the clinicians to €153 169.
Costs due to patient travelling were based on data from 
The Health Enterprises’ Centre for Patient Journeys. 
According to regional guidelines, all patients under-
going pembrolizumab therapy were referred to the two 
main hospitals, UNN in Tromsø and NH in Bodø. In 
the docetaxel or pemetrexed alternative, patients were 
treated at their local hospitals. Consequently, the distri-
bution of the patients within the region and their nearest 
hospital offering the actual therapy was employed when 
calculating travelling expenses.
Patient shares were included according to the price list 
of outpatient clinics (€39/visit).10 Similarly, the patient’s 
share was calculated €28 per CT or MR examination.10
The northern Norwegian hospitals do also have 
incomes. Consequently, when measuring budget impact, 
these incomes have to be included. Our patient clinics 
are partly financed by patients’ shares and refunding 
based on the DRG system.13 In this setting, the DRG 856D 
was employed (€1227).
Willingness to pay and loss of prognosis
In Norway, the willingness to pay is based on the severity 
of the disease.14 The severity is measured employing the 
quality-adjusted life expectancy (QALE) method. The 
mean age, among patients diagnosed with NSCLC, was 
70 years. We have no quality-of-life data for the general 
population in Norway and, therefore, we employed 
the Swedish data.15 On the basis of these data, the QALE 
of 70-year-old persons, in general, is 11 quality-adjusted 
life-years (QALYs). On the basis of the knowledge that 
NSCLC is more common among males, males having a 
shorter life expectancy and the life expectancy of patients 
undergoing second-line therapy for advanced or meta-
static NSCLC is <1 year, we calculated a loss of 10 QALYs 
among patients diagnosed with advanced or metastatic 
NSCLC. In such a setting, the willingness to pay among 
Norwegian healthcare administrators is somewhere 
between €57 000 and €68 000 per QALY.14
results
costs
We calculated 105 patients available for pembrolizumab 
therapy in northern Norway each year. Furthermore, the 
total cost of documenting the PD-L1 status, including 
bioengineer, pathologist and Dako-kit was calculated to 
a total of €301.527. The corresponding costs of radiolog-
ical examinations (CT, MR and CT-guided biopsy) were 
€60 536 and €32 398 in the pembrolizumab and docetaxel 
or pemetrexed arm, respectively. The annual drug cost 
of pembrolizumab was €5 178 026 and the administra-
tion/production cost at the pharmacy was €87 911. The 
corresponding cost of the pharmacy expenses in the 
docetaxel or pemetrexed arm was €605 551 or €37 906, 
respectively. The total increased need of nurse/oncolo-
gist/ pulmonologist resources in the pembrolizumab arm 
was estimated €153 169. Travel expenses in the pembroli-
zumab arm and docetaxel or pemetrexed arm were 
calculated as €430 909 and €95 144, respectively.
Income
Norwegian hospitals get half of their funding through 
the DRG system. However, the present DRG has not 
included the cost of pembrolizumab and, consequently, 
the income does not reflect this cost. In total, the DRG 
income was calculated as €702 181 and the patient shares 
were €48 909 in the pembrolizumab alternative. The 
corresponding figures in the docetaxel or pemetrexed 
arm was €302 775 and €23 427, respectively.
budget impact
The total cost implementing pembrolizumab in the special-
ised healthcare in northern Norway was €5.5 million and 
the annual net budget influencing €5.0 million. The 
mean increased cost per patient treated was €48 000. An 
overview is shown in table 1.
cost-effectiveness
On the basis of the budget impact of € 5.0 million and 
the willingness to pay between €57 000 and 68,000, about 
80 life-years have to be gained per year to reach the level 
of recommended use. Consequently, each patient treated 
(105 patients/year) with pembrolizumab in northern 
Norway should gain a mean life expectancy of 9 months 
to make this therapy cost-effective.
sensitivity analysis
A one-way sensitivity analysis was done to clarify the robust-
ness of the model. The following variables were included 
in the analysis and varied by +/−20%: patient share, DRG 
income, travelling expenses, pharmacy administration 
cost, drug costs, radiology and PD-L1 testing. Details are 
shown in the tornado diagram in figure 2. Except for drug 
costs, the other factors had only minor impact on the 
budget. Consequently, variations in the price of pembroli-
zumab due to currency fluctuations and negotiations over 
price will have significant impact on Norwegian hospitals’ 
budgets.
dIscussIon
The annual impact of pembrolizumab on the Northern 
Norwegian hospitals’ budget was €5.0 million. The 
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Table 1 An overview of the budget impact of implementing pembrolizumab in second-line therapy of non-small cell lung 
cancer
Cost Pembrolizumab Docetaxel or pemetrexed Budget impact
  PD-L1 testing €301 527 €0 €301 527
  Radiology (CT, MR) €60 536 €32 398 €28 138
  Drug costs €5 178 026 €605 551∗ €4 572 475
  Pulmonologist/oncologist/nurse €153 169 €0 €153 169
  Pharmacy €87 911 €37 906† €50 005
  Travelling expenses €430 909 €95 144 €335 765
Income
  DRG refunding (50%) €702 181 €302 775 €399 406
  Patient shares €48 909 €23 427 €25 482
  Budget impact €5 460 988 €444 797 € 5 016 191
*Costs based on DRG refunding (100%).
†The pharmacy-related costs were included in the DRG refunding and consequently excluded when summarising the budget impact.
DRG, diagnosis-related group.
Figure 2 Tornado diagram showing a one-way sensitivity 
analysis. 0=€5.0 million. DRG, diagnosis-related group; PD-
L1, programmed cell death ligand.
estimated mean raised cost per patient treated was 
€50 209. The sensitivity analysis documented the price of 
pembrolizumab having the greatest impact on the result. 
A mean gain of 9 months per patient treated was neces-
sary to make this treatment cost-effective, given the drug 
prices stay as of 1 January 2017.
The NMA9 concluded the cost of implementing 
pembrolizumab in second-line NSCLC in Norway to be 
€56.7 million. This national figure was based on the cost 
of pembrolizumab prior to negotiations. Knowing the 
selling price of pembrolizumab and the northern region 
having 10.3% (€5.8 million) of all patients with NSCLC, 
the true costs of implementing this drug was higher than 
these prior estimations. This was mainly due to higher 
travelling expenses and the hospitals’ membership cost 
of the Norwegian Hospital Procurement trust, included 
in the price of pembrolizumab. As we had to employ the 
refunds (according to the DRG system), and not the final 
results of negotiations over price for the comparators, the 
true difference is even greater.13
The main goal in the second-line treatment of NSCLC 
is prolonged survival/extended life and second improved 
quality of life.13 The duration of treatment and survival 
gain in the pembrolizumab alternative was difficult 
to estimate.7 In the KEYNOTE-010 study, no patients 
were treated for more than 24 months and the median 
follow-up was only 13.1 months. The 1-year survival was 
57% and 65% in the two arms. Usually, cancer treat-
ment is discontinued due to progressive disease, toxicity 
or patient’s choice. Whereas all patients had stopped 
therapy in the docetaxel arm, several patients were still 
on therapy at evaluation in the pembrolizumab arms.7 
The median duration of response was 8 months in the 
docetaxel arm and not reached in the pembrolizumab 
arms. Our estimate was based on the fact that no patient 
achieved complete remission and, consequently, no cure 
could be anticipated. Some researchers have calculated a 
‘tale of patients’ experiencing a prolonged survival.11
We have strongly indicated a significant budget impact 
by introducing pembrolizumab in second-line NSCLC 
therapy. On the basis of data from the Cancer Registry of 
Norway, it may be as long as 40 years before the incidence 
of lung cancer may start to drop, due to fewer smokers. 
The CRN has estimated that the total numbers of new 
lung cancers will increase to 3700 new cases per year in 
2025.4 Consequently, the influence on hospitals’ budgets 
will obviously grow.
We did not report the treatment duration calculated in 
the pembrolizumab arm. This is a significant limitation 
and was due to secrecy. Trade secrets can be worth tens 
of hundreds of millions of dollars, and damage awards in 
trade secret litigation have been high.16 Our concern was 
due to the agreement between the manufacturer (MSD) 
and the Norwegian Hospital Procurement Trust, making 
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it illegal to report the sale price of pembrolizumab in 
Norway. This has become a growing problem world-
wide, making it difficult to undertake and publish health 
economic analysis on new drugs. The aggressive effort by 
manufacturers to enforce price confidentiality has been 
commented by several authors. Lerner and colleagues17 
pointed on the fact that secrecy prevents hospitals from 
revealing prices to third parties that may help them nego-
tiate prices. The price of the drug itself was the major 
cost in our analysis. Consequently, significant variations 
in cost may end up in various national conclusions with 
regard to cost-effectiveness. Unfortunately, this variation 
in pricing cannot be explored due to price confidenti-
ality. In our neighbouring country, Sweden, significant 
differences have been revealed between the county 
councils.18 A Bloomberg report19 mentioned that health 
insurance companies buy prescription drugs the way US 
consumers buy cars: there is the sticker price (which few 
people actually pay) and there is the negotiated price. 
One of these reports19analysed 39 medicines with global 
sales of more than US$1 billion a year and showed that 
30 of them logged price increases of more than double 
the rate of inflation from 2009 to 2015. One example 
was imatinib (Glivec), launched in 2001 at a price of 
US$31 930 per year and the corresponding cost in 2015 
was US$118,000.20
There have been some advocates for disclosing costs. 
In the USA, Vermont was the first state to require drug 
makers to justify price hikes.21 Henrikson et al22 argued 
that healthcare in the USA had come to resemble a 
‘menu without prices’ for both physicians and patients, 
who systematically lacks access to the price of treatments, 
procedures and diagnostic tests. This ‘firewall’ may once 
have served an ethical purpose. However, they22 propose 
that complete price transparency for people with cancer 
should be an integral part of patient-centred care. Most 
people with cancer report wishing to discuss cancer care 
costs with their providers,23 and patient interest in price 
data is increasing.24 Trust is a crucial component of the 
entire physician patient relationship, including cost-re-
lated discussions.25
On the basis of our analysis, we cannot conclude 
whether pembrolizumab is cost-effective. This is due to 
the fact that we do not know the survival gain. However, 
the present data from the KEYNOTE-010 study7 were far 
from the needed 9 months level to make it cost-effective. 
In the total population, the median overall survival was 
10.4 months in the pembrolizumab 2 mg/kg arm and 8.5 
months in the docetaxel arm, respectively.7 However, as 
mentioned, several patients were still on therapy in the 
pembrolizumab arm when the study data were evaluated. 
In this study, we employed the recommended PD-L1 
expression level (>1% of tumour cells).7 Knowing the 
correlation between PD-L1 expression and differential 
activity of pembrolizumab, higher levels of expression 
(ie, >5%) should be explored to define the group making 
this therapy cost-effective.26
conclusion
The introduction of pembrolizumab in the second-line 
treatment of advanced or metastatic NSCLC will have signif-
icant impact on healthcare budgets in northern Norway. A 
mean survival gain of 9 months per patient treated should 
be achieved to make it cost-effective. The lack of price trans-
parency has made it impossible to run transparent health 
economic analyses. In the future, various PD-L1 expressions 
levels for initiation of therapy may be explored.
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